Hillsdale Investment Management Inc. Purchases 50 Shares of Becton, Dickinson and Company (NYSE:BDX)

Hillsdale Investment Management Inc. increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,060 shares of the medical instruments supplier’s stock after buying an additional 50 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $694,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of BDX. Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company during the fourth quarter worth about $25,000. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $29,000. Picton Mahoney Asset Management boosted its position in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 54 shares during the last quarter. Hopwood Financial Services Inc. acquired a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $39,000. Finally, Versant Capital Management Inc boosted its position in Becton, Dickinson and Company by 54.1% during the fourth quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 73 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Richard Byrd sold 459 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the sale, the executive vice president now directly owns 6,952 shares of the company’s stock, valued at approximately $1,598,960. The trade was a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,984 shares of company stock valued at $1,147,865. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.5 %

Shares of NYSE:BDX opened at $230.63 on Monday. The company has a market capitalization of $66.22 billion, a price-to-earnings ratio of 38.31, a P/E/G ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The business’s 50-day moving average is $232.58 and its 200-day moving average is $231.93. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its board has approved a stock repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

Analysts Set New Price Targets

BDX has been the subject of a number of recent analyst reports. Barclays raised their price objective on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, March 5th. Finally, Piper Sandler raised their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.